Macrogenics, Inc.

Stephen James Burke

Leslie Sydnor Johnson

Paul A Moore

Ling Ling Huang

Ezio Bonvini

Kalpana Shah

Chia-Ying Kao Lam

Liqin Liu

Gurunadh Reddy Chichili

Bhaswati Barat

Yan Zhou

Krishnan Sampathkumar

The present disclosure is provides pharmaceutical compositions, for storage and administration, comprising a human PD-1 ('hPD-1') antibody (“retifanlimab”) and buffering agents. The disclosure further provides containers and kits comprising such pharmaceutical compositions. The disclosure further provides the use of such pharmaceutical compositions, containers, and kits containing retifanlimab in the treatment of a cancer, and in certain aspects treatment of a cancer expressing PD-L1.

Pharmaceutical compositions of a PD-1 antibody and use of the same

The present invention relates to Tri-Specific Binding Molecules, which are multi-chain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Binding Domains may be selected such that the Tri-Specific Binding Molecules are capable of binding to any three different epitopes. Such epitopes may be epitopes of the same antigen or epitopes of two or three different antigens. In a preferred embodiment, one of such epitopes will be capable of binding to CD3, the second of such epitopes will be capable of binding to CD8, and the third of such epitopes will be capable of binding to an epitope of a Disease-Associated Antigen. The invention also provides a novel ROR1-binding antibody, as well as derivatives thereof and uses for such compositions.

Multi-chain polypeptide-containing tri-specific binding molecules

Growing community of inventors

Mount Airy, MD, United States of America

Stephen James Burke